However, ANPEP expression is downregulated in sacubitril/valsartan-resistant (SVR) patients with heart failure, indicating that it may be involved in the development of SVR and serve as a potential therapeutic target or biomarker (Su et al., 2023). Here, ANPEP is linked to heart failure.